ClinicalTrials.gg
Not yet recruitingNCT07091214Updated Jul 29, 2025

Molecular Transcriptomics in Diagnosing Pediatric Kidney Transplant Rejection: the PANDA-Kids-ATLAS Study

An observational study in Kidney Rejection Transplant, sponsored by Paris Translational Research Center for Organ Transplantation. Not yet recruiting at 1 site in France. Open to participants aged 0 Years to 21 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-07-29.

Sponsored by Paris Translational Research Center for Organ Transplantation · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
600
Ages
0 Years to 21 Years
Sex
All
01

Study summary

Children with kidney failure have markedly increased mortality and face repeated transplantation over their lifetime due to limited allograft half-life (12-15 years). Current biopsy-based diagnoses of rejection (using Banff 2022 criteria) suffer from variability and limited sensitivity. PANDA-Kids-ATLAS will analyze up to 600 pediatric FFPE kidney biopsies across multiple centres using the Banff Human Organ Transplant (B-HOT) NanoString panel to develop and validate molecular classifiers of AMR, TCMR and related phenotypes. A secure REDCap database will integrate molecular, pathological and clinical data, aiming to improve early detection, personalize therapy, and enhance long-term graft survival and patient quality of life.

Read the detailed description

The study builds a deeply phenotyped international cohort of pediatric transplant patients (\<21 years) with both retrospective (2014-present) and prospective (through Dec 2027) biopsy sampling. Four diagnostic "baskets" (classical AMR/TCMR; probable ABMR/MVI; other injury; normal) will each contribute equal numbers of cases for classifier validation (Part A) and real-world prevalence samples for outcome association (Part B). FFPE blocks will be centrally reviewed via Banff 2022 automated and expert pathologist interpretation, then processed by NanoString nCounter® using the 770-gene B-HOT panel. Stratified random sampling, robust QC, and integration with clinical/immunological parameters in REDCap will underpin molecular classifier development and validation. Follow-up includes clinical outcomes and graft function monitoring.

02

Conditions studied

  • Kidney Rejection Transplant

Keywords

  • transcriptomics
  • pediatric kidney transplantation
  • allograft rejection
  • precision diagnosis
  • molecular classifiers
03

In context

Lead sponsor

Paris Translational Research Center for Organ Transplantation is the lead sponsor of 31 studies on the registry; 7 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
0 Years to 21 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Probability sample

Study population

Pediatric kidney transplant recipients

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≤ 21 years
  • Single kidney transplant recipients (deceased or living donor)
  • Written from patients/guardians

Exclusion criteria

Exclusion Criteria:

  • Multi-organ transplantation history
  • with insufficient tissue
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
600 participants (estimated)
Patient registry
No

Groups and cohorts

  • Group 1: Classic rejection profile

    Active/chronic AMR or TCMR

  • Group 2: Other rejection profiles

    Probable AMR, MVI+DSA- C4d-, borderline or mixed rejection

  • Group 3: Other diagnoses

    CMV, CNI toxicity, recurrence, BK nephropathy

  • Group 4: Normal biopsies

    No lesions (normal biopsy results)

06

What researchers measure

Primary outcomes

  1. Identification of Molecular Classifiers for Kidney Allograft Rejection Using Banff Human Organ Transplant (B-HOT) Gene Panel via NanoString nCounter®

    Molecular signatures (molecular classifiers) will be identified through bulk transcriptomic analysis utilizing the validated Banff Human Organ Transplant (B-HOT) gene panel, consisting of 770 rejection- and tolerance-related genes. Formalin-fixed, paraffin-embedded (FFPE) biopsy samples from pediatric kidney transplant recipients will be processed and analyzed using the NanoString nCounter® platform. Specifically, molecular classifiers distinguishing classical antibody-mediated rejection (AMR), T-cell mediated rejection (TCMR), and novel Banff 2022 antibody-mediated rejection-related categories-including microvascular inflammation with donor-specific antibodies and negative C4d staining (MVI+DSA-C4d-) and probable antibody-mediated rejection (pABMR)-will be quantified and reported. Classifier results will be summarized as normalized gene expression profiles, enabling clear discrimination among different categories of rejection and non-rejection biopsies.

    Time frame: 3 years

Secondary outcomes

  1. Integration of Molecular Classifiers with Clinical Parameters into an Archetype-based Diagnostic System for Kidney Allograft Rejection

    An archetype-based diagnostic framework will be generated by integrating transcriptomic molecular classifiers (quantified using NanoString nCounter® platform and Banff Human Organ Transplant (B-HOT) gene panel) with clinical parameters. Clinical parameters include patient demographics (age, sex), transplant characteristics, and clinical outcomes (e.g., serum creatinine, estimated glomerular filtration rate (eGFR), proteinuria, biopsy indication). The integrated diagnostic system will provide archetype-based patient profiles to enhance diagnostic precision and personalized clinical management. Aggregation will be performed using multidimensional modeling techniques (principal component analysis, cluster analyses) and classification algorithms (logistic regression, random forest), providing composite diagnostic archetypes. Unit of measure: Composite diagnostic archetype (multidimensional categorical profile)

    Time frame: 3 years

  2. Integration of Molecular Classifiers with Biological and Immunological Parameters into an Archetype-based Diagnostic System for Kidney Allograft Rejection

    An archetype-based multidimensional diagnostic framework will be developed by combining transcriptomic molecular classifiers (from the NanoString nCounter® platform and B-HOT gene panel) with biological and immunological parameters. Specifically, this will include immunological markers such as donor-specific antibodies (DSA), C4d staining, complement factors, and inflammatory biomarkers (e.g., cytokines, chemokines, immune cell subset analysis). The integration will be conducted through bioinformatics approaches and supervised machine learning models, culminating in archetypal patient classification based on immune and biological profiles. Unit of measure: Composite immuno-biological archetype (multidimensional categorical profile)

    Time frame: 3 years

Other outcomes

  1. Correlation of Archetype-based Diagnostic Profiles with Kidney Allograft Clinical Outcomes

    The correlation between archetype-based diagnostic profiles (derived from molecular, clinical, biological, and immunological data integration) and kidney allograft clinical outcomes will be assessed. Clinical outcomes include: 1) Incidence of acute rejection episodes (percentage \[%\] of patients experiencing biopsy-proven acute rejection, confirmed via Banff 2022 criteria). 2) Allograft survival rate (% graft survival, defined as a functioning graft without dialysis dependence or retransplantation). 3) Allograft function decline (rate of decline in eGFR \[mL/min/1.73 m²/year\], calculated from serum creatinine using the Schwartz pediatric formula). Each of these clinical outcomes will be individually correlated with the diagnostic archetype profiles using statistical analyses such as Kaplan-Meier survival curves, Cox proportional hazard models (for allograft survival and rejection-free survival), and regression analysis (for eGFR decline).

    Time frame: 3 years

07

Study locations

1 site
  • Paris Institute for Transplantation and Organ Regeneration (PITOR)
    Paris, 75015, France
08

References and documents

Publications

  • Sablik M, Sannier A, Raynaud M, Goutaudier V, Divard G, Astor BC, Weng P, Smith J, Garro R, Warady BA, Zahr RS, Twombley K, Dharnidharka VR, Dandamudi RS, Fila M, Huang E, Sellier-Leclerc AL, Tonshoff B, Rabant M, Verine J, Del Bello A, Berney T, Boyer O, Catar RA, Danger R, Giral M, Yoo D, Girardin FR, Alsadi A, Gourraud PA, Morelon E, Le Quintrec M, Try M, Villard J, Zhong W, Bestard O, Budde K, Chauveau B, Couzi L, Brouard S, Hogan J, Legendre C, Anglicheau D, Aubert O, Kamar N, Lefaucheur C, Loupy A. Microvascular Inflammation of Kidney Allografts and Clinical Outcomes. N Engl J Med. 2025 Feb 20;392(8):763-776. doi: 10.1056/NEJMoa2408835. Epub 2024 Oct 24. PubMed 39450752 ↗
  • Halloran PF, Madill-Thomsen KS, Bohmig G, Bromberg J, Budde K, Barner M, Mackova M, Chang J, Einecke G, Eskandary F, Gupta G, Myslak M, Viklicky O, Akalin E, Alhamad T, Anand S, Arnol M, Baliga R, Banasik M, Bingaman A, Blosser CD, Brennan D, Chamienia A, Chow K, Ciszek M, de Freitas D, Deborska-Materkowska D, Debska-Slizien A, Djamali A, Domanski L, Durlik M, Fatica R, Francis I, Fryc J, Gill J, Gill J, Glyda M, Gourishankar S, Grenda R, Gryczman M, Hruba P, Hughes P, Jittirat A, Jurekovic Z, Kamal L, Kamel M, Kant S, Kasiske B, Kojc N, Konopa J, Lan J, Mannon R, Matas A, Mazurkiewicz J, Miglinas M, Muller T, Narins S, Naumnik B, Patel A, Perkowska-Ptasinska A, Picton M, Piecha G, Poggio E, Bloudickova SR, Samaniego-Picota M, Schachtner T, Shin S, Shojai S, Sikosana MLN, Slatinska J, Smykal-Jankowiak K, Solanki A, Veceric Haler Z, Vucur K, Weir MR, Wiecek A, Wlodarczyk Z, Yang H, Zaky Z. Subthreshold rejection activity in many kidney transplants currently classified as having no rejection. Am J Transplant. 2025 Jan;25(1):72-87. doi: 10.1016/j.ajt.2024.07.034. Epub 2024 Aug 6. PubMed 39117038 ↗
  • Mengel M, Loupy A, Haas M, Roufosse C, Naesens M, Akalin E, Clahsen-van Groningen MC, Dagobert J, Demetris AJ, Duong van Huyen JP, Gueguen J, Issa F, Robin B, Rosales I, Von der Thusen JH, Sanchez-Fueyo A, Smith RN, Wood K, Adam B, Colvin RB. Banff 2019 Meeting Report: Molecular diagnostics in solid organ transplantation-Consensus for the Banff Human Organ Transplant (B-HOT) gene panel and open source multicenter validation. Am J Transplant. 2020 Sep;20(9):2305-2317. doi: 10.1111/ajt.16059. Epub 2020 Jun 27. PubMed 32428337 ↗
  • Zielinski D, Goutaudier V, Sablik M, Divard G, Aubert O, Piedrafita A, Mezine F, Dagobert J, Certain A, Robin B, Gueguen J, Rabant M, Duong van Huyen JP, Sannier A, Randoux-Lebrun C, Maanaoui M, Lionet A, Gibier JB, Gnemmi V, Le Quintrec M, Chauveau B, Vermorel A, Couzi L, Bestard O, Elias M, Louis K, Rosales IA, Smith RN, Kung VL, Anglicheau D, Legendre C, Del Bello A, Huang E, Adam B, Kamar N, Colvin RB, Mengel M, Lefaucheur C, Loupy A. Molecular diagnosis of kidney allograft rejection based on the Banff Human Organ Transplant gene panel: A multicenter international study. Am J Transplant. 2025 Aug;25(8):1631-1642. doi: 10.1016/j.ajt.2025.04.025. Epub 2025 May 8. PubMed 40345499 ↗
  • Fichtner A, Gauche L, Susal C, Tran TH, Waldherr R, Krupka K, Guzzo I, Carraro A, Oh J, Zirngibl M, Weitz M, Konig J, Buscher A, Berta L, Simon T, Awan A, Rusai K, Topaloglu R, Peruzzi L, Printza N, Kim JJ, Weber LT, Melk A, Pape L, Rieger S, Patry C, Hocker B, Tonshoff B; CERTAIN study group. Incidence, risk factors, management strategies, and outcomes of antibody-mediated rejection in pediatric kidney transplant recipients-a multicenter analysis of the Cooperative European Paediatric Renal Transplant Initiative (CERTAIN). Pediatr Nephrol. 2025 Feb;40(2):491-503. doi: 10.1007/s00467-024-06487-2. Epub 2024 Sep 16. PubMed 39283519 ↗

Individual participant data

Plan to share: Yes — molecular classifiers results

Supporting information: Study protocol, Informed consent form

Time frame: after the completion and publication of the study

Access criteria: Participating centres' PI can contact the PI of the study for access in their center's results.

Data sharing details ↗ · certain-registry.kikli.uni-heidelberg.de

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Sep 2025; primary completion for Dec 2028, 39 months later.

How these figures are worked out, and which studies are left out of them.

Registered
May 22, 2025
First posted
Jul 29, 2025
StartEst.
Sep 1, 2025
Primary completionEst.
Dec 31, 2028
CompletionEst.
Dec 31, 2028
Last update
Jul 29, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 29, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07091214
Lead sponsor
Paris Translational Research Center for Organ Transplantation
Collaborators
Paris Cardiovascular Research Center (Inserm U970)
Responsible party
Sponsor
First posted
Jul 29, 2025
Start date
Sep 1, 2025 (estimated)
Primary completion
Dec 31, 2028 (estimated)
Completion
Dec 31, 2028 (estimated)
Last update
Jul 29, 2025

Study contacts

Evgenia Preka, MD, PhDc
Contact
evgenia.preka@gmail.com
+33 1 44 23 60 00
Evgenia Preka, MD, PhDc
principal investigator · INSERM U970
Alexandre Loupy, MD, PhD
study chair · INSERM U970
Valentin Goutaudier, MD, PhD
study chair · INSERM U970

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion